05:32 AM EST, 01/23/2025 (MT Newswires) -- (Updates with the stock move in the headline and the first paragraph.)

Exicure ( XCUR ) shares were up more than 28% in premarket activity Thursday after the company said overnight that it agreed to acquire all the shares of GPCR Therapeutics USA, a subsidiary of South Korea's GPCR Therapeutics.

Exicure ( XCUR ) and GPCR have also entered into a licensing and collaboration agreement to further develop certain GPCR technologies and commercialize them, the company said late Wednesday.

Financial terms were not disclosed.

Under the agreement, Exicure ( XCUR ) is to pay GPCR milestone payments upon reaching specific milestone events relating to clinical trials, marketing authorizations, and net sales, as well as a recurring royalty payment based on at least 10% of net sales, the company said.

Price: 13.30, Change: +2.93, Percent Change: +28.25